Co-Founder and CEO, GlycoMimetics, Inc.
Rachel King is co-founder and CEO of GlycoMimetics, Inc. (NASDAQ: GLYC), a publically traded biotechnology company. Before founding GlycoMimetics, she was an Entrepreneur in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Rachel went to NEA after serving as a senior vice president of Novartis Corporation. Before joining Novartis, she spent 10 years with the biotechnology company Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. Rachel also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. She is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Rachel now serves on the boards of Novavax, Inc. (NASDAQ: NVAX) and the University of Maryland BioPark. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.
Rachel is married to John King, and they have two grown children.